{"id":64882,"date":"2026-05-09T21:21:51","date_gmt":"2026-05-09T13:21:51","guid":{"rendered":"https:\/\/flcube.com\/?p=64882"},"modified":"2026-05-09T21:21:52","modified_gmt":"2026-05-09T13:21:52","slug":"curegene-pharmaceutical-secures-rmb-300-million-series-c-to-advance-global-clinical-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64882","title":{"rendered":"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline"},"content":{"rendered":"\n<p><strong>Shanghai CureGene Pharmaceutical Co., Ltd.<\/strong> announced the completion of its <strong>Series C financing round<\/strong>, raising <strong>over RMB 300 million<\/strong> (approximately <strong>USD 44.1 million<\/strong>). The round was <strong>led by Walvax Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300142:SHE\">SHE: 300142<\/a>), with participation from existing investor <strong>TaiLong VC<\/strong>, <strong>Qianhai Ark Venture Capital<\/strong>, and <strong>Shenzhen Credit Guarantee<\/strong>. Proceeds will accelerate the <strong>global clinical development<\/strong> of the company&#8217;s core pipeline assets across cardiovascular, metabolic, and infectious disease indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Round<\/strong><\/td><td>Series C<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td>RMB 300+ million (USD 44.1 million)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Walvax Biotechnology Co., Ltd. (SHE: 300142)<\/td><\/tr><tr><td><strong>Participating Investors<\/strong><\/td><td>TaiLong VC, Qianhai Ark Venture Capital, Shenzhen Credit Guarantee<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Global clinical development of core pipeline assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Founded in 2018, CureGene has rapidly advanced multiple first-in-class and next-generation therapeutic candidates through strategic drug design and innovative mechanisms of action.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-pipeline-assets\">Core Pipeline Assets<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-evategrel-first-in-class-p2y12-inhibitor\">Evategrel \u2013 First-in-Class P2Y12 Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Formulations:<\/strong> Both intravenous and oral<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Thiol-hydrolyzing prodrug design<\/li>\n\n\n\n<li><strong>Onset of Action:<\/strong> &lt;15 minutes (IV); &lt;30 minutes (oral)<\/li>\n\n\n\n<li><strong>Key Advantage:<\/strong> Completely overcomes &#8220;clopidogrel resistance&#8221; affecting ~58% of Chinese population<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses significant unmet need in antiplatelet therapy for acute coronary syndromes<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cg-0416-next-generation-thr-\u03b2-agonist\">CG-0416 \u2013 Next-Generation THR-\u03b2 Agonist<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Highly selective liver-targeting thyroid hormone receptor beta (THR-\u03b2) agonist<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Weight management and metabolic liver disease<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Phase I clinical trials initiated<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Liver-specific targeting minimizes systemic side effects while maximizing metabolic benefits<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cg-1999-hepatitis-b-functional-cure-vaccine\">CG-1999 \u2013 Hepatitis B Functional Cure Vaccine<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Therapeutic vaccine inducing specific immune responses against hepatitis B virus (HBV)<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Demonstrates clear synergistic effects with siRNA\/ASO therapies in animal models<\/li>\n\n\n\n<li><strong>Key Outcomes:<\/strong><\/li>\n\n\n\n<li>Accelerated reduction of hepatitis B surface antigen (HBsAg)<\/li>\n\n\n\n<li>Effective suppression of viral rebound after siRNA\/ASO discontinuation<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Addresses functional cure paradigm in chronic HBV infection<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-amp-market-context\">Strategic &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiovascular Innovation:<\/strong> Evategrel&#8217;s ability to overcome clopidogrel resistance represents a major advancement for China&#8217;s large cardiovascular patient population<\/li>\n\n\n\n<li><strong>Metabolic Disease Focus:<\/strong> CG-0416 enters the competitive but high-value NASH\/obesity market with differentiated liver-targeting approach<\/li>\n\n\n\n<li><strong>HBV Cure Strategy:<\/strong> CG-1999 positions CureGene in the emerging functional cure space for hepatitis B, a significant burden in Asia<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Funding specifically allocated for global clinical development signals international commercial aspirations<\/li>\n\n\n\n<li><strong>Investor Validation:<\/strong> Walvax&#8217;s lead investment demonstrates confidence in CureGene&#8217;s platform and pipeline quality<\/li>\n<\/ul>\n\n\n\n<p>This financing round provides CureGene with substantial resources to advance multiple high-potential assets simultaneously, positioning the company as an emerging player in China&#8217;s innovative biopharmaceutical landscape.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, financing outcomes, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64884,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1575,1152,332],"class_list":["post-64882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-curegene-pharmaceutical","tag-she-300142","tag-walvax-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising over RMB 300 million (approximately USD 44.1 million). The round was led by Walvax Biotechnology Co., Ltd. (SHE: 300142), with participation from existing investor TaiLong VC, Qianhai Ark Venture Capital, and Shenzhen Credit Guarantee. Proceeds will accelerate the global clinical development of the company&#039;s core pipeline assets across cardiovascular, metabolic, and infectious disease indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64882\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline\" \/>\n<meta property=\"og:description\" content=\"Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising over RMB 300 million (approximately USD 44.1 million). The round was led by Walvax Biotechnology Co., Ltd. (SHE: 300142), with participation from existing investor TaiLong VC, Qianhai Ark Venture Capital, and Shenzhen Credit Guarantee. Proceeds will accelerate the global clinical development of the company&#039;s core pipeline assets across cardiovascular, metabolic, and infectious disease indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64882\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-09T13:21:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-09T13:21:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0903-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline\",\"datePublished\":\"2026-05-09T13:21:51+00:00\",\"dateModified\":\"2026-05-09T13:21:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0903-1.webp\",\"keywords\":[\"CureGene Pharmaceutical\",\"SHE: 300142\",\"Walvax Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64882#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64882\",\"name\":\"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0903-1.webp\",\"datePublished\":\"2026-05-09T13:21:51+00:00\",\"dateModified\":\"2026-05-09T13:21:52+00:00\",\"description\":\"Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising over RMB 300 million (approximately USD 44.1 million). The round was led by Walvax Biotechnology Co., Ltd. (SHE: 300142), with participation from existing investor TaiLong VC, Qianhai Ark Venture Capital, and Shenzhen Credit Guarantee. Proceeds will accelerate the global clinical development of the company's core pipeline assets across cardiovascular, metabolic, and infectious disease indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64882\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0903-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0903-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64882#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising over RMB 300 million (approximately USD 44.1 million). The round was led by Walvax Biotechnology Co., Ltd. (SHE: 300142), with participation from existing investor TaiLong VC, Qianhai Ark Venture Capital, and Shenzhen Credit Guarantee. Proceeds will accelerate the global clinical development of the company's core pipeline assets across cardiovascular, metabolic, and infectious disease indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64882","og_locale":"en_US","og_type":"article","og_title":"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline","og_description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising over RMB 300 million (approximately USD 44.1 million). The round was led by Walvax Biotechnology Co., Ltd. (SHE: 300142), with participation from existing investor TaiLong VC, Qianhai Ark Venture Capital, and Shenzhen Credit Guarantee. Proceeds will accelerate the global clinical development of the company's core pipeline assets across cardiovascular, metabolic, and infectious disease indications.","og_url":"https:\/\/flcube.com\/?p=64882","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-09T13:21:51+00:00","article_modified_time":"2026-05-09T13:21:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0903-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64882#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64882"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline","datePublished":"2026-05-09T13:21:51+00:00","dateModified":"2026-05-09T13:21:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64882"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0903-1.webp","keywords":["CureGene Pharmaceutical","SHE: 300142","Walvax Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64882#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64882","url":"https:\/\/flcube.com\/?p=64882","name":"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64882#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0903-1.webp","datePublished":"2026-05-09T13:21:51+00:00","dateModified":"2026-05-09T13:21:52+00:00","description":"Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising over RMB 300 million (approximately USD 44.1 million). The round was led by Walvax Biotechnology Co., Ltd. (SHE: 300142), with participation from existing investor TaiLong VC, Qianhai Ark Venture Capital, and Shenzhen Credit Guarantee. Proceeds will accelerate the global clinical development of the company's core pipeline assets across cardiovascular, metabolic, and infectious disease indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64882#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64882"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64882#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0903-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0903-1.webp","width":1080,"height":608,"caption":"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64882#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0903-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64882"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64882\/revisions"}],"predecessor-version":[{"id":64885,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64882\/revisions\/64885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64884"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}